COMMUNIQUÉS West-GlobeNewswire
-
STERIS to Host a Conference Call for Fiscal 2026 Fourth Quarter and Full Year Results on May 12, 2026
21/04/2026 -
Rgenta Therapeutics Announces RGT-61159 Clinical Poster Presentation at the Upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
21/04/2026 -
Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting
21/04/2026 -
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
21/04/2026 -
CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study
21/04/2026 -
TELA Bio to Announce First Quarter 2026 Financial Results
21/04/2026 -
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
21/04/2026 -
Oculis Publishes Invitation to the Annual General Meeting
21/04/2026 -
Vapofil Claims Evaluated (2026 Official Website Scam WARNING Update) Avoid Fake Complaints & Hidden Risks
21/04/2026 -
Precede Biosciences Launches Precede Bio Insight™, a Genome-Wide Liquid Biopsy for Functional Tumor Biology at AACR 2026
21/04/2026 -
Resolutions of the Annual General Meeting 2026 of Bavarian Nordic A/S
21/04/2026 -
Premier Health Announces Management Transition
21/04/2026 -
Neuro Salt Ingredients Decoded: Deciphering the Difference Between Official Website Hype & Actual Health Benefits
21/04/2026 -
Cytokinetics to Announce First Quarter Results on May 5, 2026
21/04/2026 -
Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease
21/04/2026 -
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
21/04/2026 -
Oculis Publishes Invitation to the Annual General Meeting
21/04/2026 -
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
21/04/2026 -
Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026
21/04/2026
Pages